We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Correspondence |

Use of Mitoxantrone in Neuromyelitis Optica—Reply

Su-Hyun Kim, MD; Ho Jin Kim, MD, PhD
Arch Neurol. 2011;68(8):1086-1087. doi:10.1001/archneurol.2011.171.
Text Size: A A A
Published online


In reply

We thank Kitley and colleagues for their interest in our article and their comments. All patients described in our article1 were referred to our center from other hospitals owing to frequent relapses despite treatment. In fact, many of them were treated with interferon beta after a diagnosis of optic-spinal multiple sclerosis. As Kitley and colleagues pointed out, based on the recent studies,2,3 treatment with interferon beta might have contributed to the high pretreatment relapse rate, which could have made mitoxantrone treatment appear more efficacious in our study. However, what we want to emphasize is that 6 cycles of mitoxantrone induction treatment effectively suppressed the highly active disease status, even if it might result from inappropriate treatment.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





August 1, 2011
Joanna L. Kitley, BMBS, MRCP; Maria Isabel Leite, MB, DPhil; Lucy A. E. Matthews, BMBS, MRCP; Jacqueline Palace, DM, FRCP
Arch Neurol. 2011;68(8):1086-1087. doi:10.1001/archneurol.2011.170.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Therapy of NMO spectrum disorders. Ann Indian Acad Neurol 2015;18(Suppl 1):S16-23.